Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1356 results about "Arthritis" patented technology

A joint disorder which features inflammation of one or more joints.

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Pharmaceutical compositions comprising a tolfenamic acid

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Citrullinated SAA polypeptide and application of citrullinated SAA polypeptide in preparation of rheumatoid arthritis diagnosis product

The invention discloses a citrullinated SAA polypeptide and application thereof in preparation of a rheumatoid arthritis diagnosis product, the amino acid sequence of the citrullinated SAA polypeptide is DKYFHA-Cit-GNYDAAK-Cit-GPGGA, through the polypeptide, the citrullinated autoantigen B cell epitope of SAA and a corresponding autoantibody, namely an anti-citrullinated SAA polypeptide antibody (anti-CAP), are identified. The expression level of anti-CAP in RA patients is obviously higher than that of other disease control groups and healthy groups, and the anti-CAP has better positive rate in early RA, ESR / CRP normal RA and anti-CCP antibody / RF negative RA, and provides a new strategy for diagnosis of RA.
Owner:PEOPLES HOSPITAL PEKING UNIV

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Intelligent response type chitosan gel system and preparation method thereof

The invention relates to intelligent response type chitosan gel and a preparation method thereof. The intelligent response type chitosan gel is prepared from active oxygen response type lipidosome, a chitosan solution, a sodium glycerophosphate solution, a medicine and the like. According to the invention, a drug-loaded liposome with active oxygen response is introduced, and a nanoliposome with negative electricity is loaded into chitosan-sodium glycerophosphate gel in a charge adsorption manner, so that a response type multifunctional composite hydrogel system is prepared. After the intelligent response drug-loaded hydrogel system is injected into a human body, gel is formed in situ, the lubricating capacity of the hydrogel system is enhanced through introduction of lipidosome, and friction force in an articular cavity is reduced. Meanwhile, the liposome can be split through the process of removing active oxygen, and the medicine is controlled in the articular cavity in a controlled release manner. Therefore, the intelligent gel can delay the progress of arthritis through the synergistic effect of lubrication, oxidation resistance and inflammation resistance.
Owner:HANGZHOU SINGCLEAN MEDICAL PROD

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

AI combined MRI and clinical JIA diagnosis system and storage medium

The invention belongs to the technical field of intelligent diagnosis, and particularly relates to an AI combined MRI and clinical JIA diagnosis system and a storage medium. According to the system disclosed by the invention, the early auxiliary diagnosis of the juvenile idiopathic arthritis is carried out by combining artificial intelligence with multi-dimensional and multi-modal information of multi-sequence MRI images of knee joints of children and various clinical information. The main technology of the method is child knee joint tissue segmentation based on deep learning, a multi-dimensional feature extraction strategy based on a segmentation result, and disease classification based on multi-modal feature integration and deep learning. By integrating the multi-dimensional features of the multi-sequence MRI images and fusing different modal features such as image information and clinical information, an auxiliary diagnosis result with high accuracy can be provided. The technology provided by the invention is beneficial to the realization of early diagnosis and early treatment of juvenile idiopathic arthritis, and has a very good application prospect.
Owner:SICHUAN UNIV

Application of citrullinated endolectin-1 polypeptide in preparation of rheumatoid arthritis diagnosis product

The invention discloses application of citrullinated endolectin-1 polypeptide in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the citrullinated endolectin-1 polypeptide is GD-Cit-WSSQQGSKAVYPE, and the amino acid sequence of the citrullinated endolectin-1 polypeptide is GD- The product is used for detecting the content of the anti-citrullinated endolectin-1 polypeptide antibody in a biological sample of a patient, and the antibody level is remarkably different from that of normal healthy people and other common rheumatism immune disease patients easily confused with rheumatoid arthritis in the body of an RA patient. The kit has good sensitivity for common RA, RA with normal ESR and CRP, and anti-CCP antibody / RF negative RA patients, and has good supplementary diagnostic value for RA diagnosis.
Owner:PEOPLES HOSPITAL PEKING UNIV

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Bacterial polypeptide Gfo and application thereof in preparation of rheumatoid arthritis diagnosis product

The invention discloses a bacterial polypeptide Gfo and application thereof in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the bacterial polypeptide Gfo is LNSHGFLPETE. A diagnostic product prepared from the bacterial polypeptide Gfo can effectively detect that the level of an anti-bacterial polypeptide Gfo antibody in a biological sample of a rheumatoid arthritis patient is obviously higher than that of healthy people and other rheumatoid immune diseases similar to rheumatoid arthritis. In addition, in CCP antibody and RF negative patients, the increase is still significant. Therefore, the antibacterial polypeptide Gfo antibody is an important biomarker of rheumatoid arthritis, and provides an effective new method for diagnosis of RA, especially diagnosis of serum-negative RA.
Owner:PEOPLES HOSPITAL PEKING UNIV

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Pharmaceutical compositions comprising meloxicam

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Owner:AXSOME THERAPEUTICS INC

Disease modifying Anti-rheumatic drug combination therapies

PCT designated stage expiredWO2025099187A1AntipyreticDigestive systemAutoimmune conditionProgressive disorder
The invention provides combination therapies comprising disease modifying anti-rheumatic drugs and mitochondrial complex I modulator (MCIM) compounds, which find utility in the medical field of inflammatory and progressive disorders, for example autoimmune diseases such as arthritis.
Owner:ISTESSO 2 LTD

Lactobacillus rhamnosus BN02 for improving joint inflammation and promoting bone health, metagen and application of lactobacillus rhamnosus BN02 and metagen

The invention discloses a lactobacillus rhamnosus capable of improving joint inflammation and promoting bone health, a metagen and application of the lactobacillus rhamnosus, the lactobacillus rhamnosus is lactobacillus rhamnosus BN02, the lactobacillus rhamnosus is preserved in China General Microbiological Culture Collection Center on November 27, 2023, and the preservation number is CGMCC No.29133. The lactobacillus rhamnosus can be used for improving joint inflammation and promoting bone health. The lactobacillus rhamnosus BN02 can reduce the number of gram-negative bacteria in intestinal tracts of arthritis patients, increase the synthesis amount of bone collagen, and is beneficial to promoting absorption of vitamin C by the intestinal tracts, improving joint inflammation and promoting bone health.
Owner:湖南益百益优生物科技有限公司

Interleukin-17A / F inhibitor as well as preparation method and application thereof

The invention belongs to the technical field of chemical drugs, provides an interleukin-17A / F inhibitor as well as a preparation method and application thereof, and particularly relates to a compound as shown in a general formula (I), or a racemate, an isomer or medicinal salt thereof, which is used for treating diseases such as psoriasis and arthritis as the IL-17A / F inhibitor.
Owner:SHENZHEN SALUBRIS PHARMA CO LTD

Rheumatoid arthritis diagnosis product and system and application thereof

The invention discloses a rheumatoid arthritis diagnosis product and system and application thereof, and relates to the technical field of rheumatoid arthritis. The diagnostic marker comprises calcium, a ratio of arginine to ornithine, a ratio of phenylalanine to tyrosine, an anti-cyclic citrullinated peptide antibody and lysine. The invention provides a biomarker capable of accurately diagnosing rheumatoid arthritis RA, which comprises five indexes, namely calcium, the proportion of arginine to ornithine, the proportion of phenylalanine to tyrosine, an anti-cyclic citrullinated peptide antibody (anti-CCP) and lysine. The five indexes have the technical advantages of few indexes and excellent diagnosis performance. A diagnosis model constructed based on the five indexes has good sensitivity, specificity and accuracy. The kit can be used for diagnosis of rheumatoid arthritis.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Application method of targeted MTHFD2 in preparation of medicine for treating rheumatoid arthritis bone destruction

The invention relates to the field of application of medicines for treating rheumatoid arthritis, and discloses an application method of targeted MTHFD2 in preparation of medicines for treating bone destruction of rheumatoid arthritis, (1) the level of MTHFD2 in knee joints of rheumatoid arthritis patients and mice is increased; (2) the expression of MTHFD2 is up-regulated in the process of differentiating osteoclast precursor cells from mice and humans into osteoclasts; (3) the MTHFD2 inhibitor can significantly inhibit differentiation of osteoclasts from mice and humans; (4) MTHFD2 gene silencing can inhibit differentiation of mouse-derived osteoclasts, MTHFD2 gene overexpression can promote differentiation of osteoclasts, and reliability of MTHFD2 as a therapeutic target is verified; and (5) the MTHFD2 inhibitor can improve the bone destruction of arthritis mice and increase the bone tissue density, which prompts that the targeted MTHFD2 is useful for the treatment or prevention of rheumatoid arthritis and other diseases.
Owner:UNIV OF SCI & TECH OF CHINA

Multi-modal image feature fused knee joint fraction prediction method and system

The invention discloses a knee joint fraction prediction method and system fused with multi-modal image features. The knee joint fraction prediction method fused with the multi-modal image features obtains a knee joint prediction fraction of an object through five steps. The method has the beneficial effects that 1, deep learning, radiomics characteristics and combined clinical characteristics are fused, the magnetic resonance T1 sequence image of the knee joint is processed and analyzed, the popliteal artery ROI is marked, and related radiomics and deep network characteristics are extracted; compared with traditional single feature analysis, the method has the advantages that more comprehensive and accurate disease assessment is provided, and the accuracy and reliability of knee osteoarthritis prediction are improved. And 2, the method is based on the obvious relation between the popliteal artery and the knee bone joint, innovatively analyzes the image features of the popliteal artery and combines clinical data, so that the method not only can predict the occurrence and progress of the osteoarthritis more accurately in an earlier stage, but also obviously improves the prediction effect.
Owner:SOUTHERN MEDICAL UNIVERSITY

BCW theory-based personalized rehabilitation exercise method for patients with rheumatoid arthritis

The invention relates to the technical field of digital health, in particular to a personalized rehabilitation exercise method for rheumatoid arthritis patients based on a BCW theory, which comprises the following steps: acquiring joint angle change and calculating a pain delay response coefficient, detecting fluctuation of supporting force and stabilizing force to obtain a joint load tolerance value, analyzing respiratory coordination to generate a respiratory coordination index, and performing rehabilitation training on the respiratory coordination index. The method comprises the steps that a joint angle sensor and pain intensity data are analyzed, a BCW capacity factor weight value is generated in a weighted mode, a fuzzy control algorithm is input to conduct hierarchical mapping adjustment on action amplitude frequency and rest intervals, and exercise adaptability feedback data are generated through monitoring completion degree and pain feedback. The exercise intensity is dynamically adjusted in real time through a data model, a personalized rehabilitation scheme is automatically optimized, the problems that subjective feedback is relied on, and physiological changes cannot be responded in time are solved, more accurate exercise amount adjustment is provided, the situation that the joint burden is increased due to improper exercise intensity is avoided, and the rehabilitation process is effectively promoted.
Owner:THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV

Application of CTHRC1 inhibitor in preparation of medicine for preventing and / or treating arthritis

The invention relates to an application of a CTHRC1 inhibitor in preparation of a medicine for preventing and / or treating arthritis. Specifically, the invention provides application of an inhibitor or an antagonist of a CTHRC1 gene or a protein thereof, the inhibitor or the antagonist is used for preparing a composition or a preparation, and the composition or the preparation is used for (a) preventing and / or treating arthritis-related diseases; and / or (b) inhibiting cartilage cell senescence.
Owner:SHANGHAI YANGZHI REHABILITATION HOSPITAL